LONGO, MIRIAM
LONGO, MIRIAM
Dipartimento di Scienze Cliniche e di Comunità
DIETARY INTERVENTIONS TARGETING GLUCOSE METABOLISM AND HYPERINSULINEMIA: A NEW TRANSLATIONAL PERSPECTIVE FOR THE MANAGEMENT OF ACUTE INTERMITTENT PORPHYRIA
2023 M. Longo
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
2023 E. Paolini, M. Longo, M. Meroni, G. Tria, A. Cespiati, R. Lombardi, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
2022 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
2022 M. Meroni, M. Longo, E. Paolini, R. Lombardi, R. Piciotti, P. Francione, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
The α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. DI PIERRO, P. Dongiovanni
The rs599839 a>g variant disentangles cardiovascular risk and hepatocellular carcinoma in nafld patients
2021 M. Meroni, M. Longo, E. Paolini, A. Alisi, L. Miele, E.R. De Caro, G. Pisano, M. Maggioni, G. Soardo, L.V. Valenti, A.L. Fracanzani, P. Dongiovanni
Remodeling of mitochondrial plasticity: The key switch from NAFLD/Nash to HCC
2021 M. Longo, E. Paolini, M. Meroni, P. Dongiovanni
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
2021 M. Meroni, M. Longo, R. Lombardi, E. Paolini, C. Macchi, A. Corsini, C.R. Sirtori, A.L. Fracanzani, M. Ruscica, P. Dongiovanni
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
2021 S. Grimaudo, P. Dongiovanni, J. Pihlajamaki, M. Eslam, H. Yki-Jarvinen, R.M. Pipitone, G. Baselli, C. Camma, V. Di Marco, M. Enea, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxi, J. George, S. Romeo, L. Valenti, S. Petta
Genetics is of the essence to face NAFLD
2021 M. Meroni, M. Longo, G. Tria, P. Dongiovanni
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
2021 N. Panera, M. Meroni, M. Longo, A. Crudele, L. Valenti, E. Bellacchio, L. Miele, V. D'Oria, E. Paolini, M. Maggioni, A.L. Fracanzani, A. Alisi, P. Dongiovanni
$\upalpha$-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study [alpha-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study]
2021 M. Longo, E. Paolini, M. Meroni, L. Duca, I. Motta, A.L. Fracanzani, E. Di Pierro, P. Dongiovanni
Genetics, immunity and nutrition boost the switching from nash to hcc
2021 P. Dongiovanni, M. Meroni, M. Longo, S. Fargion, A.L. Fracanzani
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
2021 M. Longo, M. Meroni, E. Paolini, C. Macchi, P. Dongiovanni
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
2020 P. Dongiovanni, M. Meroni, S. Petta, M. Longo, A. Alisi, G. Soardo, L. Valenti, L. Miele, S. Grimaudo, G. Pennisi, G. Antonio, D. Consonni, S. Fargion, A.L. Fracanzani
MAFLD in COVID-19 patients: an insidious enemy
2020 P. Dongiovanni, M. Meroni, M. Longo, A.L. Fracanzani
Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
2020 M. Meroni, M. Longo, P. Dongiovanni